• Anna Olsen, Belinda Lawton, Robyn Dwyer, Meng-Wong Taing, Chun Ka Lai Joyce KLJ School of Pharmacy, University of Queensland, Brisbane St Lucia, Queensland, 4072, Australia., Samantha Hollingworth, and Suzanne Nielsen.
• National Centre for Epidemiology and Population Health, Australian National University, Acton ACT, 0200, Australia. Electronic address: anna.olsen@anu.edu.au.
• Int. J. Drug Policy. 2019 Jul 1; 69: 46-52.

BackgroundOpioid overdose is a significant public health issue among people who use pharmaceutical opioids and/or heroin. One response to reducing overdose deaths is to expand public access to naloxone. The Australian Therapeutic Goods Administration down-scheduled naloxone from prescription only (S4) to pharmacist only over-the-counter (OTC, schedule 3) in February 2016. There is little research examining pharmacists' perspectives or experiences of this change.MethodsThirty-seven semi-structured interviews with Australian community pharmacists were conducted in 2016-2017 to investigate pharmacists' attitudes to and experiences of OTC naloxone. Transcripts were thematically analysed, guided by a broad interest in facilitators and barriers to OTC supply.ResultsAround half of the pharmacists were aware of the down-scheduling and only two had provided OTC naloxone. Core barriers to pharmacist provision of OTC naloxone included limited understanding of opioid overdose, confusion about the role and responsibilities of pharmacists in providing OTC naloxone, concerns about business, stigma related to people who inject drugs (PWID) and system-level challenges.ConclusionPharmacy provision of OTC naloxone offers an important opportunity to reduce overdose mortality. Our study suggests this opportunity is yet to be realised and highlights several individual- and structural-level impediments hindering the expansion of public access to naloxone via community pharmacies. There is a need to develop strategies to improve pharmacists' knowledge of OTC naloxone and opioid overdose as well as to address other logistical and cultural barriers that limit naloxone provision in pharmacy settings. These need to be addressed at the individual level (training) as well as the system level (information, regulation and supply).Copyright © 2019. Published by Elsevier B.V.

23 keywords...

hide…